difficile vaccine ... Oct. 23, 2024 — Maternal antibodies passed across the placenta can interfere with the response to the malaria vaccine, which would explain its lower efficacy in infants ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The launch follows the arrival of the first shipment of 186,000 doses of the malaria vaccines to Sudan in October. The ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

The continent is being drenched in an avalanche of medical disinformation with the aim of undermining western influence ...

Maryland’s biotech industry plays a pivotal role in advancing global health initiatives. This vibrant sector is characterized ...

showing very encouraging results and paving the way for future malaria vaccine development. A robust industrial partner, GSK Biologicals, has shown commitment to the project for more than 20 years ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...

GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...

Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...